Modulation of adrenergic receptors during left ventricular hypertrophy development and after regression by captopril

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 4, 1999, Pages 505-511

  Martínez, María Luisa ^a   Fernández Tomé, Paz ^a   López Miranda, Visitación ^a   Colado, Maria Isabel ^a   Delgado, Carmen ^a,b  

^a Instituto Nacional de Toxicologia   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

Author keywords

Adrenergic receptors; Angiotensin converting enzyme inhibitors; Cardiac hypertrophy; Plasma norepinephrine; Regression of cardiac hypertrophy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; MALE; NEUROMODULATION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; CAPTOPRIL; DISEASE MODELS, ANIMAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA;

EID: 0032831002     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199910000-00005     Document Type: Article

References (43)

1. Coraboeuf E. Anomalies des mouvements ioniques dans l'hypertrophie et l'insuffisance cardiaques. Therapie 1992;47: 171-9.
2. Pianno M. Cellular and signalling mechanism of cardiac hypertrophy. J Cardiovasc Nurs 1994;8:1-26.
3. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89-101.
4. Katz AM. The cardiomyopathy of overload. N Engl J Med 1991; 322:100-10.
5. Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982;51:787-801.
6. Clark WA, Rudnick SJ, La press JJ, Andreson LC, La Pointe M. Regulation of hypertrophy in cultured adult heart cells. Circ Res 1993;73:1163-76.
7. Chiba M, Shida M, Miyazaki Y, Koga Y, Toshima H. Role of adrenergic receptor systems in canine left ventricular hypertrophy. J Mol Cell Cardiol 1989;21:38-47.
8. Zierhut W, Zimmer HG. Significance of *p-1X α and β adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989;65:1417-25.
9. 1-adrenoceptors: an overview. Pharmacol Rev 1993;45:147-75.
10. 1-adrenoceptor: inotropic effect and physiologic and pathologic implications. Life Sci 1997;60:1305-18.
11. Ganguly PK, Lee SL, Bearnish RE, Dhalla N. Altered sympathetic system and adrenoceptors during development of cardiac hypertrophy. Am Heart J 1989;118:520-5.
12. Foster KA, Hock CE, Reibel DK. Altered responsiveness of hypertrophied rat hearts to alpha- and beta-adrenergic stimulation. J Mol Cell Cardiol 1991;23:91-101.
13. Matsui H, Makino N, Kenichi Y, Nakanishi H, Hata T, Yanaga T. Modulation of adrenergic receptors during development of cardiac hypertrophy. J Hypert 1994;12:1353-7.
14. Leenen FHH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans. Am J Med 1987; 82:969-78.
15. Dunn FG, Ventura HO, Messerli FH, Kobrin Y, Frohlich ED. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 1987;76:254-8.
16. Pfeffer J, Pfeffer Y, Mirsky Y, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Med Sci 1982;79:3310-4.
17. Rossi MA, Peres LC, Preto R. Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy. Am Heart J 1992; 124:700-9.
18. Squirre IB, Reid JL. Interactions between the renin-angiotensin system and the autonomic nervous system. In: Robertson JI, Nicholls MG, eds. The renin-angiotensin system. St. Louis: Mosby, 1993;37:1-16.
19. Gomez AM, Benitah JP, Henzel D, Vinet A, Lorente P, Delgado C. Modulation of electrical heterogeneity by compensated hypertrophy in rat left ventricle. Am J Physiol 1997;272:H1078-86.
20. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein, utilizing the principle of protein dry-binding. Anal Biochem 1976;72:248-52.
21. Esler M, Jennings G, Lambert G, Meredith I, Home M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and function. Physiol Rev 1990;70:963-85.
22. 1- but not to β-adrenoceptor stimulation in isolated hearts from spontaneously hypertensive rats. J Hypertens 1992;10:143-8.
23. 1-adrenoceptors. Eur J Pharmacol 1980;67:115-8.
24. Vatner DE, Homcy CI, Sit SP, Mandera WT, Vatner SF. Effects of pressure overload LVH on β-adrenergic receptors and responsiveness to catecholamines. J Clin Invest 1984;73:1473-82.
25. Limas C, Limas CJ. Reduced number of β-adrenergic receptors in the myocardium of spontaneously hypertensive rats. Biochem Biophys Res Commun 1978;83:710-4.
26. Ayobe MH, Tarazi RC. β-Receptors and contractile reserve in left ventricular hypertrophy. Hypertension 1983;5(suppl I):I192-7.
27. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
28. Nishimura H, Kubota J, Okabe M, Ueyama M, Kawamura K. Effects of lisinopril upon cardiac hypertrophy, central and peripheral hemodynamics and neurohumoral factors in spontaneously hypertensive rats. J Hypertens 1992;10:431-6.
29. Dart AM, Du XJ. Unexpected drug effects on autonomic function during myocardial ischaemia. Cardiovasc Res 1993;27:906-14.
30. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
31. Regan CP, Anderson PG, Bishop SP, Berecek H. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic banded rats. Am J Physiol 1996;271:H906-13.
32. Pegram BL, Ishise S, Frohlich ED. Effect of methyldopa clonidine and hydralazine on cardiac mass and hemodynamics in Wistar-Kyoto and spontaneously hypertensive rats. Cardiovasc Res 1982; 16:40-6.
33. Dominiak P, Elfrath A, Turck D. Effects of chronic treatment with ramipril a new ACE blocking agent, on presynaptic sympathetic nervous system of SHR. Clin Exp Hypertens 1987;9:369-73.
34. Ledda F, Marchetti P, Mugelli A. Studies on the positive inotropic effect of phenilephrine: a comparison with isoprenaline. Br J Pharmacol 1975;54:83-90.
35. Endoh M. Adrenoceptors and the myocardial inotropic response: do ot and β receptors sites functionally coexist? Trends Auton Pharmacol 1982;2:303-22.
36. Skomedal T, Schiander I, Osnes JB. Prazosin-sensitive components of the inotropic response to norepinephrine in rabbit heart. J Pharmacol Exp Ther 1988;247:1204-10.
37. Skomedal T, Aass H, Osnes JB. Both α and β-adrenoceptors mediated components contributed to final inotropic response to norepinephrine in rat heart. J Pharmacol Exp Ther 1990;252:853-8.
38. Danziger RS, Sakai M, Lakatta EG, Hansford RG. Interactive α-and β-adrenergic actions of norepinephrine in rat cardiac myocytes. J Mol Cell Cardiol 1990;22:111-23.
39. 1- and β-adrenergic interactions on L-type calcium current in cardiac myocytes. Pflugers Arch 1992;421:397-9.
40. 2+ currents in cardiac ventricular myocytes. Circ Res 1996;79:184-93.
41. Bing O, Matsushito S, Fanburg B, Levine H. Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res 1971;28:234-45.
42. Lecarpentier Y, Waldenström A, Clergue M, et al. Major alterations in relaxation during cardiac hypertrophy induced by aortic stenosis in guinea-pig. Circ Res 1987;61:107-16.
43. Gómez AM, Valdivia H, Cheng H, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997;276:800-6.